You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
道指期货现升逾700点 据报对抗新冠药「瑞德西韦」临床试验效果显着
阿思达克 04-17 08:17
医药新闻网站《Statnews》报道,美国药厂吉利德科学(Gilead Sciences)新抗病毒药物「瑞德西韦」(Remdesivir)的临床试验显示,对治疗新型冠状病毒效果显着,刺激美股期货急升。道指期货现涨781点或3.33%至24,188点,标指及纳指期货则分别升2.91%及2.19%。

芝加哥一间医院招募125名病人参与瑞德西韦的临床试验,当中113人病情严重,但大多数患者从发烧等严重症状中迅速好转过来,并已经出院。吉利德科学股价於盘後急升16.41%,报89.1美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account